Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CAB Payments reports improving momentum heading into H2

(Sharecast News) - B2B FX and cross-border payments group CAB Payments said it made "good strategic progress" over the first half following the transformation plan announced last year, with the business in a stable position with momentum heading into the second half. Total income over the first half was up 3% over the six months to 30 June at £51.8m, though down 8% on last year due to the non-repeat of a dislocated currency in the first half of 2024 and the impact of macro uncertainty among some clients.

Nevertheless, active client numbers increased to 573 from 546 at the end of 2024.

The company said its financial performance has now "stabilised" with adjusted EBITDA rising 8% from the second half of 2024 to £13.1m, though down 30% on last year.

"We are demonstrating good progress in executing our strategic priorities evidenced by a return to modest half-on-half revenue growth. Work continues to be done but the business is now better positioned to drive diversified and sustainable revenue growth, supported by more active clients, a deeper network and entry into new markets," said chief executive Neeraj Kapur.

The company has continued to diversify its income streams, with 27% of total income now driven the top five currency corridors, down from 32% the year before and 49% in the first half of 2023.

CAB Payments now has a wider spread of income derived across FX spreads, fees and interest rates, it said.

Looking ahead, the company expects an improved performance in the second half and continues to guide to year-on-year income growth for 2025 along with "more meaningful growth in 2026".

Shares were up 3.3% at 51.49p by 0852 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.